DexCom (DXCM) Tops Q2 EPS by 4c; updates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to DexCom (DXCM) Tops Q2 EPS by 4c; updates guidance
July 26, 2024 6:34 AM EDT
RBC Capital analyst Shagun Singh lowered the price target on DexCom (NASDAQ: DXCM) to $145.00 (from $165.00) while maintaining a Outperform rating.
The analyst comments "DXCM delivered Q2 results with a 3% sales miss, but 10% EPS beat. Three factors impacted sales: below expectations US salesforce... More
July 26, 2024 6:18 AM EDT
Baird analyst Jeff Johnson downgraded DexCom (NASDAQ: DXCM) from Outperform to Neutral with a price target of $80.00 (from $161.00).
The analyst comments "Downgrading to Neutral/lowering price target to $80. We struggle to fully understand last night's 2Q miss/sizable cut to 2024... More
July 26, 2024 5:57 AM EDT
UBS analyst Danielle Antalffy lowered the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $163.00) while maintaining a Buy rating.
The analyst comments "Shares traded down ~37% after-hours due to DXCM's ~3.5% top-line sales miss and now lower (~$300M) FY24 guidance with full-year sales expected to grow +11-13% organic vs. +17-21%, previously. And while this comes as quite a surprise to us given our view that CGM (Continuous Glucose Monitoring)... More
July 26, 2024 5:40 AM EDT
Canaccord Genuity analyst William J. Plovanic lowered the price target on DexCom (NASDAQ: DXCM) to $89.00 (from $145.00) while maintaining a Buy rating.
The analyst comments "Bottom line: Dexcom reported a surprising Q2 topline miss, and guidance reset, with revenue of $1,004M (+15.3% Y/Y) missing both our $1,049M estimate and consensus of $1,037M. On... More
